NantOmics is a leader in molecular testing, offering solutions to accurately assess genomic and proteomic alterations in cancer for personalized treatment options. As a member of the NantWorks ecosystem, NantOmics employs an integrated panomic approach to inform precision medicine. By combining DNA sequencing, RNA sequencing, and quantitative proteomics, NantOmics provides comprehensive testing capabilities that deliver a molecular profile of a patient's cancer.

Using our proprietary analytical platform, we offer molecular diagnostic capabilities that provide actionable intelligence and molecularly driven decision support at the point of care. Whole genome sequencing, RNA sequencing, and quantitative proteomics allow us to detect tumor-specific alterations, confirm mutations, and measure clinically important proteins. Our extensive knowledge database, encompassing hundreds of oncogenes and thousands of cellular pathways, enables us to identify genomic and proteomic alterations with the highest clinical relevance to each patient's tumor.

These alterations are then matched to targeted drugs that may be effective against tumors containing the specific alteration. Choose NantOmics for comprehensive molecular testing and personalized treatment options in the field of precision medicine